"Encouraged by the success of checkpoint inhibitors in fighting some cancers, many companies are developing antibodies that block the LAG-3-MHC-II interaction, including Tesaro(TSR033), Novartis (LAG525), Bristol-Myers Squibb (relatlimab) and F-star (FS118). The safety and efficacy of these candidate immunotherapies are being evaluated in trials for several advanced cancers."
Soooo....could someone with a better understanding of the science than I, please explain if our little Efti has been on the right track?
Thanks in advance.
Immutep, page-48
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.3¢ |
Change
0.008(2.46%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.5¢ | 30.5¢ | $146.4K | 466.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 114589 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 286626 | 19 |
View Market Depth
| Last trade - 10.56am 25/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
